Antibiotic resistance problems with Helicobacter pylori

被引:110
作者
Alarcón, T [1 ]
Domingo, D [1 ]
López-Brea, M [1 ]
机构
[1] Hosp Univ Princesa, Dept Clin Microbiol, Madrid 28006, Spain
关键词
Helicobacter pylori; metronidazole; clarithromycin; resistance; susceptibility methods;
D O I
10.1016/S0924-8579(99)00051-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Helicobacter pylori is very susceptible in vitro to most antibiotics, but when they are used in the clinical setting, eradication of the bacteria from the gastric mucosa is not obtained. Dual or triple therapy including two of the following antibiotics: amoxicillin, tetracycline, metronidazole or clarithromycin, plus a proton pump inhibitor, bismuth salt or ranitidine bismuth citrate is the most frequently used. Various in vitro susceptibility methods have been used: disk diffusion, agar dilution and Epsilometer test (E-test). Metronidazole resistance among H. pylori strains is now found worldwide, and resistance rates vary according to the population studied. It is higher in developing than in developed countries and it could reach 80-90% in Africa. The prevalence on clarithromycin resistance is much lower, usually below 10%, although very high values are reported in Peru. Infection with metronidazole- or clarithromycin-resistant H. pylori strains is correlated with treatment failure when using regimens including these antibiotics. (C) 1999 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:19 / 26
页数:8
相关论文
共 93 条
  • [1] Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin -: Influence on treatment outcome
    Adamek, RJ
    Suerbaum, S
    Pfaffenbach, B
    Opferkuch, W
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (03) : 386 - 389
  • [2] Alarcón T, 1998, J CLIN MICROBIOL, V36, P1165
  • [3] In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori
    Alarcon, T
    Domingo, D
    Sanchez, I
    deRojas, FD
    LopezBrea, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (12) : 937 - 940
  • [4] [Anonymous], 1994, INFECT HELICOBACTER, V61, P177
  • [5] Bamba H, 1997, AM J GASTROENTEROL, V92, P659
  • [6] HIGH PREVALENCE OF HELICOBACTER-PYLORI METRONIDAZOLE RESISTANCE IN MIGRANTS TO EAST LONDON - RELATION WITH PREVIOUS NITROIMIDAZOLE EXPOSURE AND GASTRODUODENAL DISEASE
    BANATVALA, N
    DAVIES, GR
    ABDI, Y
    CLEMENTS, L
    RAMPTON, DS
    HARDIE, JM
    FELDMAN, RA
    [J]. GUT, 1994, 35 (11) : 1562 - 1566
  • [7] METRONIDAZOLE-RESISTANT HELICOBACTER-PYLORI
    BECX, MCJM
    JANSSEN, AJHM
    CLASENER, HAL
    DEKONING, RW
    [J]. LANCET, 1990, 335 (8688) : 539 - 540
  • [8] Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis
    Blandizzi, C
    Malizia, T
    Gherardi, G
    Costa, F
    Marchi, S
    Marveggio, C
    Natale, G
    Senesi, S
    Bellini, M
    Maltinti, G
    Campa, M
    Del Tacca, M
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (01) : 75 - 82
  • [9] Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance
    Buckley, MJM
    Xia, HX
    Hyde, DM
    Keane, CT
    OMorain, CA
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (10) : 2111 - 2115
  • [10] Buckley MJM, 1997, CURR OPIN GASTROEN, V13, P56